Singapore markets closed

Arvinas, Inc. (ARVN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
41.28-0.05 (-0.12%)
At close: 04:00PM EDT
41.28 0.00 (0.00%)
After hours: 04:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close41.33
Open41.71
Bid41.19 x 200
Ask41.34 x 400
Day's range40.84 - 41.98
52-week range13.57 - 53.08
Volume478,476
Avg. volume754,727
Market cap2.811B
Beta (5Y monthly)1.96
PE ratio (TTM)N/A
EPS (TTM)-6.62
Earnings date03 May 2024 - 07 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est70.89
  • GlobeNewswire

    Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

    - Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) -NEW HAVEN, Conn., March 18, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Noah Berkowitz, M.D., Ph.D., to the role of Chief Medical Officer and a member of the Executive Committee reporting to President and Chief Executive Officer John Houston, Ph.D. Eff

  • GlobeNewswire

    Arvinas to Participate in Upcoming Investor Conferences

    NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences: Leerink Partners Global Biopharma Conference on Tuesday, March 12. Ron Peck, M.D., chief medical officer, and Randy Teel, Ph.D., interim chief financial officer, will participate in a fireside chat. A live audio webcast

  • Simply Wall St.

    Arvinas, Inc. (NASDAQ:ARVN) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

    It's shaping up to be a tough period for Arvinas, Inc. ( NASDAQ:ARVN ), which a week ago released some disappointing...